Compare SWBI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWBI | CBIO |
|---|---|---|
| Founded | 1852 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 637.4M | 537.5M |
| IPO Year | 2000 | 2013 |
| Metric | SWBI | CBIO |
|---|---|---|
| Price | $13.97 | $14.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $14.00 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 576.1K | 333.3K |
| Earning Date | 06-17-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 36.67 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $523,845,000.00 | $18,500.00 |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | $279.20 |
| P/E Ratio | $233.67 | ★ N/A |
| Revenue Growth | ★ 10.36 | N/A |
| 52 Week Low | $8.14 | $8.72 |
| 52 Week High | $17.56 | $27.41 |
| Indicator | SWBI | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 58.63 | N/A |
| Support Level | $13.83 | N/A |
| Resistance Level | $14.32 | N/A |
| Average True Range (ATR) | 0.52 | 0.00 |
| MACD | 0.17 | 0.00 |
| Stochastic Oscillator | 93.58 | 0.00 |
Smith & Wesson Brands Inc is a U.S.-based company engaged in manufacturing and selling firearms. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The company sells its products under the Smith and Wesson and Gemtech brands, which are used for defense, law enforcement, hunting, and sporting purposes. Geographically, it sells products globally, with maximum income being generated by the U.S. market from its handgun products.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.